Levroxa 750mg Tablet contains Levetiracetam, an antiepileptic agent indicated for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. This medication is typically prescribed as adjunctive therapy in adults and pediatric patients aged four years and above. Levroxa 750mg Tablet is administered orally, with dosage individualized based on patient response and clinical condition. Common adverse effects include somnolence, dizziness, fatigue, and behavioral symptoms such as irritability or agitation, which generally diminish over time. It is essential to monitor patients for mood changes and suicidal ideation during therapy. Dose adjustments may be necessary in patients with renal impairment. Levroxa should be used cautiously in pregnant or breastfeeding women, weighing potential benefits against risks. Patients are advised not to discontinue therapy abruptly to avoid increased seizure frequency. Regular follow-up and adherence to prescribed dosing are critical to optimize therapeutic outcomes and minimize adverse effects. Levroxa 750mg Tablet should be stored at room temperature, away from moisture and heat.